Photo of Yakup Ergün from obdh.com.tr
Sep 20, 2024, 08:16
Yakup Ergün: Nivolumab/Relatlimab or Nivolumab/Ipilimumab in TNBC
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:
“Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in TNBC with high TILs: BELLINI trial
Stage I-II, node negative, TILs ≥50%, 30 patients
- pCR
- Nivo+IPI – 33%
- Nivo+RELA – 47%
Remarkable efficacy of chemotherapy-free immunotherapy for immunogenic TNBC”
Source: Yakup Ergün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 09:22
Dec 21, 2024, 09:06
Dec 21, 2024, 09:00
Dec 21, 2024, 08:51
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37
Dec 21, 2024, 08:29
Dec 21, 2024, 08:12